Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yiqi Yangyin Formula in Primary Sjogren's Syndrome
NCT07145060Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Sep 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in primary Sjögren's syndrome comparing Yiqi Yangyin Formula with Placebo (2 arms). Primary endpoint: Unstimulated Whole Saliva flow rate at Week 12. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Yiqi Yangyin Formula
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT07145060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145060.